The initial studies reviewed by Heneka and colleagues, which explored the effects mediated by PPARγ on neurological disorders, showed that selective inflammatory drugs, which do not exert any PPARγ ligand activity, failed to show a clinical benefit in AD [36]. The gene discussed is PPARG; the disease is Alzheimer disease.